Bank of America Issues Pessimistic Forecast for DaVita (NYSE:DVA) Stock Price

DaVita (NYSE:DVA) had its target price lowered by Bank of America from $145.00 to $140.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has an underperform rating on the stock.

A number of other research analysts have also issued reports on the stock. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Friday, August 22nd. Barclays reduced their price target on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research report on Friday, August 8th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, DaVita currently has a consensus rating of “Reduce” and an average price target of $158.00.

DaVita Stock Performance

Shares of NYSE:DVA opened at $133.08 on Wednesday. The company’s 50 day moving average price is $138.45 and its two-hundred day moving average price is $141.54. DaVita has a 12-month low of $126.07 and a 12-month high of $179.60. The firm has a market cap of $9.52 billion, a PE ratio of 13.09, a PEG ratio of 0.95 and a beta of 1.13. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the prior year, the business posted $2.00 EPS. The business’s revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts predict that DaVita will post 10.76 earnings per share for the current year.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares of the company’s stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. raised its stake in DaVita by 17.6% during the second quarter. Osaic Holdings Inc. now owns 7,574 shares of the company’s stock worth $1,082,000 after buying an additional 1,133 shares during the last quarter. Neuberger Berman Group LLC raised its stake in DaVita by 197.2% during the second quarter. Neuberger Berman Group LLC now owns 194,235 shares of the company’s stock worth $27,669,000 after buying an additional 128,871 shares during the last quarter. State of Wyoming raised its stake in DaVita by 6.0% during the second quarter. State of Wyoming now owns 2,759 shares of the company’s stock worth $393,000 after buying an additional 156 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in DaVita during the second quarter worth $239,000. Finally, FORA Capital LLC bought a new position in DaVita during the second quarter worth $1,308,000. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.